{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T10:51:01Z","timestamp":1785840661994,"version":"3.56.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ejps.2026.107446","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T09:58:13Z","timestamp":1769075893000},"page":"107446","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Minimizing aggregates when nebulizing antibody Fab fragments: high thermostability and high concentration are key"],"prefix":"10.1016","volume":"221","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-6534-5287","authenticated-orcid":false,"given":"Josi Ann","family":"Steinke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Louis","family":"Destruel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Weiche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Dengl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregoire","family":"Schwach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Pohlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlon J.","family":"Hinner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"32","key":"10.1016\/j.ejps.2026.107446_bib0001","doi-asserted-by":"crossref","first-page":"21215","DOI":"10.1039\/D3CP02639F","article-title":"New insights into the protein stabilizing effects of trehalose by comparing with sucrose","volume":"25","author":"Ahlgren","year":"2023","journal-title":"Phys. Chem. Chem. Phys.: PCCP"},{"issue":"3","key":"10.1016\/j.ejps.2026.107446_bib0002","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/pro.2029","article-title":"Probing protein stability and proteolytic resistance by loop scanning: a comprehensive mutational analysis","volume":"21","author":"Ahmad","year":"2012","journal-title":"Protein sci.: publ. Protein Soc."},{"issue":"9","key":"10.1016\/j.ejps.2026.107446_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e19478","article-title":"Comparative stability study and aggregate analysis of Bevacizumab marketed formulations using advanced analytical techniques","volume":"9","author":"Bana","year":"2023","journal-title":"Heliyon"},{"issue":"2","key":"10.1016\/j.ejps.2026.107446_bib0004","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ejpb.2012.07.004","article-title":"Impact of lyoprotectants for the stabilization of biodegradable nanoparticles on the performance of air-jet, ultrasonic, and vibrating-mesh nebulizers","volume":"82","author":"Beck-Broichsitter","year":"2012","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"1","key":"10.1016\/j.ejps.2026.107446_bib0005","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/s41467-021-20949-3","article-title":"DutaFabs are engineered therapeutic Fab fragments that can bind two targets simultaneously","volume":"12","author":"Beckmann","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejps.2026.107446_bib0006","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.chroma.2018.04.009","article-title":"Conformational changes of antibodies upon adsorption onto hydrophobic interaction chromatography surfaces","volume":"1552","author":"Beyer","year":"2018","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.ejps.2026.107446_bib0007","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejpb.2020.04.006","article-title":"Protein stability during nebulization: mind the collection step!","volume":"152","author":"Bodier-Montagutelli","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"3","key":"10.1016\/j.ejps.2026.107446_bib0008","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1042\/bj2070641","article-title":"A correlation between protein thermostability and resistance to proteolysis","volume":"207","author":"Daniel","year":"1982","journal-title":"Biochem. J."},{"issue":"1","key":"10.1016\/j.ejps.2026.107446_bib0009","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ejpb.2013.03.011","article-title":"Insulin-like growth factor-I aerosol formulations for pulmonary delivery","volume":"85","author":"Germershaus","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"1-2","key":"10.1016\/j.ejps.2026.107446_bib0010","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ijpharm.2007.02.035","article-title":"The influence of fluid physicochemical properties on vibrating-mesh nebulization","volume":"339","author":"Ghazanfari","year":"2007","journal-title":"Int. J. Pharm."},{"issue":"2","key":"10.1016\/j.ejps.2026.107446_bib0011","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/0192623320976094","article-title":"BSTP review of 12 case studies discussing the challenges, pathology, immunogenicity, and mechanisms of inhaled biologics","volume":"49","author":"Hall","year":"2021","journal-title":"Toxicol. Pathol."},{"issue":"2","key":"10.1016\/j.ejps.2026.107446_bib0012","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1177\/0192623320960023","article-title":"Case studies discussing the pathology, immunogenicity, and proposed mechanism of toxicity of an inhaled anti-tgf\u03b2 humanized fab antibody in non-Human primates and mice","volume":"49","author":"Hall","year":"2021","journal-title":"Toxicol. Pathol."},{"issue":"2","key":"10.1016\/j.ejps.2026.107446_bib0013","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ejpb.2014.03.001","article-title":"That's cool!\u2013nebulization of thermolabile proteins with a cooled vibrating mesh nebulizer","volume":"87","author":"Hertel","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2026.107446_bib0014","series-title":"Pulmonary delivery of pharmaceutical proteins by means of vibrating mesh nebulisation","author":"Hertel","year":"2014"},{"key":"10.1016\/j.ejps.2026.107446_bib0015","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.addr.2014.10.003","article-title":"Protein stability in pulmonary drug delivery via nebulization","volume":"93","author":"Hertel","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"4","key":"10.1016\/j.ejps.2026.107446_bib0016","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1513\/pats.200409-046TA","article-title":"Deposition of inhaled particles in the human respiratory tract and consequences for regional targeting in respiratory drug delivery","volume":"1","author":"Heyder","year":"2004","journal-title":"Proc. Am. Thorac. Soc."},{"issue":"3","key":"10.1016\/j.ejps.2026.107446_bib0017","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0031-6865(96)00014-3","article-title":"Theoretical relationship of lung deposition to the fine particle fraction of inhalation aerosols","volume":"71","author":"Hickey","year":"1996","journal-title":"Pharm. Acta Helv."},{"issue":"3","key":"10.1016\/j.ejps.2026.107446_bib0018","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2337\/dc24-1832","article-title":"A randomized trial comparing inhaled insulin plus basal insulin versus usual care in adults with type 1 diabetes","volume":"48","author":"Hirsch","year":"2025","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.ejps.2026.107446_bib0019","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/j.xphs.2023.02.010","article-title":"Protein aggregates in inhaled biologics: challenges and considerations","volume":"112","author":"Ibrahim","year":"2023","journal-title":"J. Pharm. Sci."},{"issue":"5","key":"10.1016\/j.ejps.2026.107446_bib0020","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1073\/pnas.1616408114","article-title":"Biophysical properties of the clinical-stage antibody landscape","volume":"114","author":"Jain","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"20","key":"10.1016\/j.ejps.2026.107446_bib0021","doi-asserted-by":"crossref","first-page":"4922","DOI":"10.1021\/acs.jpcb.4c00022","article-title":"Comparison of sucrose and trehalose for protein stabilization using differential scanning calorimetry","volume":"128","author":"Jonsson","year":"2024","journal-title":"J. Phys. Chem. B"},{"issue":"10","key":"10.1016\/j.ejps.2026.107446_bib0022","doi-asserted-by":"crossref","first-page":"4219","DOI":"10.1002\/jps.21322","article-title":"Reversible self-association of a concentrated monoclonal antibody solution mediated by Fab-Fab interaction that impacts solution viscosity","volume":"97","author":"Kanai","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2026.107446_bib0023","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jcis.2019.04.060","article-title":"Linking aggregation and interfacial properties in monoclonal antibody-surfactant formulations","volume":"550","author":"Kannan","year":"2019","journal-title":"J. Colloid Interface Sci."},{"issue":"21","key":"10.1016\/j.ejps.2026.107446_bib0024","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21218037","article-title":"QSAR implementation for HIC retention time prediction of mAbs using fab structure: A comparison between structural representations","volume":"21","author":"Karlberg","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"32","key":"10.1016\/j.ejps.2026.107446_bib0025","doi-asserted-by":"crossref","first-page":"eabb0372","DOI":"10.1126\/sciadv.abb0372","article-title":"A single molecular descriptor to predict solution behavior of therapeutic antibodies","volume":"6","author":"Kingsbury","year":"2020","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.ejps.2026.107446_bib0026","article-title":"Stable high-concentration monoclonal antibody formulations enabled by an amphiphilic copolymer excipient","volume":"6","author":"Klich","year":"2023","journal-title":"Adv. Ther."},{"issue":"3","key":"10.1016\/j.ejps.2026.107446_bib0027","article-title":"The pharmaceutical industry in 2023: an analysis of FDA drug approvals from the perspective of molecules","volume":"29","author":"Torre","year":"2024","journal-title":"Mol. (Basel Switz.)"},{"key":"10.1016\/j.ejps.2026.107446_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2023.106522","article-title":"Nebulization of PEGylated recombinant human deoxyribonuclease I using vibrating membrane nebulizers: A technical feasibility study","volume":"189","author":"Mahri","year":"2023","journal-title":"Eur. J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.ejps.2026.107446_bib0029","doi-asserted-by":"crossref","DOI":"10.1186\/s43556-020-00014-z","article-title":"Developing inhaled protein therapeutics for lung diseases","volume":"1","author":"Matthews","year":"2020","journal-title":"Mol. Biomed."},{"key":"10.1016\/j.ejps.2026.107446_bib0030","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ejpb.2022.11.006","article-title":"Inhaled IgG1 antibodies: the buffering system is an important driver of stability during mesh-nebulization","volume":"181","author":"Mayor","year":"2022","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"4","key":"10.1016\/j.ejps.2026.107446_bib0031","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s13346-021-00967-w","article-title":"Inhaled antibodies: formulations require specific development to overcome instability due to nebulization","volume":"11","author":"Mayor","year":"2021","journal-title":"Drug deliv. Transl. Res."},{"issue":"2","key":"10.1016\/j.ejps.2026.107446_bib0032","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/d41573-025-00001-5","article-title":"2024 FDA approvals","volume":"24","author":"Mullard","year":"2025","journal-title":"Nat. Rev., Drug Discov."},{"issue":"2","key":"10.1016\/j.ejps.2026.107446_bib0033","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejpb.2010.02.014","article-title":"A toxicological evaluation of inhaled solid lipid nanoparticles used as a potential drug delivery system for the lung","volume":"75","author":"Nassimi","year":"2010","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2026.107446_bib0034","unstructured":"NEBU-TEC med. Produkte Eike Kern GmbH: Gebrauchsanweisung: M-neb\u00ae mobile mesh nebulizer MN-300\/9. Online verf\u00fcgbar unter https:\/\/www.nebu-tec.de\/fileadmin\/user_upload\/Dateien\/Downloadcenter\/MN-300-9\/NT_MN-300-9_IFU_LAYOUT-D_E.pdf, zuletzt gepr\u00fcft am 05.03.2024."},{"issue":"8","key":"10.1016\/j.ejps.2026.107446_bib0035","doi-asserted-by":"crossref","first-page":"647","DOI":"10.4155\/tde-2017-0037","article-title":"Drug delivery to the lungs: challenges and opportunities","volume":"8","author":"Newman","year":"2017","journal-title":"Ther. Deliv."},{"issue":"12","key":"10.1016\/j.ejps.2026.107446_bib0036","doi-asserted-by":"crossref","first-page":"3305","DOI":"10.1073\/pnas.70.12.3305","article-title":"Three-dimensional structure of the Fab' fragment of a human immunoglobulin at 2,8-A resolution","volume":"70","author":"Poljak","year":"1973","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.ejps.2026.107446_bib0037","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4155\/tde-2017-0102","article-title":"Mesh nebulizers have become the first choice for new nebulized pharmaceutical drug developments","volume":"9","author":"Pritchard","year":"2018","journal-title":"Ther. Deliv."},{"issue":"5","key":"10.1016\/j.ejps.2026.107446_bib0038","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.4161\/mabs.29938","article-title":"Effect of formulation on the stability and aerosol performance of a nebulized antibody","volume":"6","author":"Respaud","year":"2014","journal-title":"mAbs"},{"issue":"6","key":"10.1016\/j.ejps.2026.107446_bib0039","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0168-9525(00)02024-2","article-title":"EMBOSS: the European Molecular Biology Open Software Suite","volume":"16","author":"Rice","year":"2000","journal-title":"Trends Genet.: TIG"},{"issue":"3","key":"10.1016\/j.ejps.2026.107446_bib0040","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14030671","article-title":"Aggregates associated with instability of antibodies during aerosolization induce adverse immunological effects","volume":"14","author":"S\u00e9cher","year":"2022","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.ejps.2026.107446_bib0041","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1023\/A:1015108115452","article-title":"Inverse relationship of protein concentration and aggregation","volume":"19","author":"Treuheit","year":"2002","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2026.107446_bib0042","article-title":"<787>Subvisible particulate matter in therapeutic protein injections","volume":"42","year":"2024"},{"key":"10.1016\/j.ejps.2026.107446_bib0043","article-title":"<788>Particulate matter in injections","volume":"42","year":"2024"},{"issue":"1","key":"10.1016\/j.ejps.2026.107446_bib0044","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s12931-019-1057-3","article-title":"Topical application of nebulized human IgG, IgA and IgAM in the lungs of rats and non-human primates","volume":"20","author":"Vonarburg","year":"2019","journal-title":"Respir. Res."},{"issue":"5","key":"10.1016\/j.ejps.2026.107446_bib0045","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1021\/acs.molpharmaceut.3c00081","article-title":"Enhanced thermal stability and reduced aggregation in an antibody fab fragment at elevated concentrations","volume":"20","author":"Zhang","year":"2023","journal-title":"Mol. Pharm."},{"issue":"2","key":"10.1016\/j.ejps.2026.107446_bib0046","first-page":"261","article-title":"Inhalable nanomedicine for lung cancer treatment","volume":"5","author":"Zhang","year":"2024","journal-title":"Smart Mater. Med."},{"issue":"12","key":"10.1016\/j.ejps.2026.107446_bib0047","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1016\/j.xphs.2022.09.004","article-title":"Exploring the protein stabilizing capability of surfactants against agitation stress and the underlying mechanisms","volume":"111","author":"Zoeller","year":"2022","journal-title":"J. Pharm. Sci."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098726000205?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098726000205?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T11:52:42Z","timestamp":1779709962000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098726000205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":47,"alternative-id":["S0928098726000205"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2026.107446","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Minimizing aggregates when nebulizing antibody Fab fragments: high thermostability and high concentration are key","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2026.107446","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107446"}}